15185-66-7

Basic information

• Product Name: (2-Amino-5-chlorophenyl)-phenylmethanona E-oxium
• Synonyms: (2-Amino-5-chlorophenyl)-phenylmethanona E-oxium;(E)-2-Amino-5-chlorobenzophenone oxime
• CAS NO: 15185-66-7
• Molecular Formula: C₁₃H₁₁ClN₂O
• Molecular Weight: 246.69
• Mol File: 15185-66-7.mol
• Article Data: 3

Chemical Properties

• Appearance: /
• CAS DataBase Reference: (2-Amino-5-chlorophenyl)-phenylmethanona E-oxium(CAS DataBase Reference)
• NIST Chemistry Reference: (2-Amino-5-chlorophenyl)-phenylmethanona E-oxium(15185-66-7)
• EPA Substance Registry System: (2-Amino-5-chlorophenyl)-phenylmethanona E-oxium(15185-66-7)

Safety Data

• Hazardous Substances Data: 15185-66-7(Hazardous Substances Data)

Usage

General Description

"(2-Amino-5-chlorophenyl)-phenylmethanona E-oxium" is a chemical compound that belongs to the oxime group of substances. It is a derivative of both amino and phenyl compounds, and its molecular structure includes a chlorine atom. It is commonly used in the field of organic chemistry for its ability to act as a nucleophile in various reactions and its potential as a building block for more complex molecules. As a result, it has applications in the synthesis of pharmaceuticals, agrochemicals, and other fine chemicals. Due to its potential reactivity and toxicological properties, it should be handled with caution and in accordance with proper safety protocols.

Upstream product

• 719-59-5 5-chloro-2-aminobenzophenone 

Downstream Products

• 2888-63-3 2-Chloracetamino-5-chlor-benzophenon-α-oxim 
• 479676-59-0 7-chloro-2-oxo-5-phenyl-3-propyl-2,3-dihydro-1H-1,4-benzodiazepin-4-ium-4-olate 

Relevant articles and documents

In vivo evaluation of substituted 3-amino-1,4-benzodiazepines as anti-depressant, anxiolytic and anti-nociceptive agents

Oxazepam (CAS 604-75-1) 4 a served as building block in the synthesis of substituted 3-amino-l,4-benzodiazepines, which were subsequently tested in various CNS animal models. The hydroxy group of oxazepam was either activated as a chloride (Method A) or as a phos- phor-oxy derivative (Method B) giving the desired 3-amino-l,4-benzodiapines 6 a- 6r in high yields with primary and secondary amines in a typical nucleophilic substitution reaction. Eighteen 3-substi- tuted 1,4-benzodiazepines were prepared and served as new chemical entities and for lead structure discovery. The mixed cholecystokinin (CCK) antagonist 6 e showed anxiolytic and antidepressant effects from 10μg/kg in mice in the elevated x-maze test and the forced swimming test. The CCK 1 antagonist 6 g has shown antidepressant effects from the same dose, but lacked anxiolytic properties. Both compounds potentiated at a dose of 0.5 mg/kg morphine antinocicep- tion with a maximum possible effect (MPE) about 35 %. By assessing initially the MPE of antinocipection for the 18 newly synthesised benzodiazepines in the tail-flick test, 4 other benzodiazepines were found active. In further in vivo evaluation the cyclohexyl derivative 6 i displayed anxiolytic, antidepressant and antinociceptive properties as single agent at a dose of 5 mg/kg without toxicity. The benzodiazepines 6i and 6p, which initially showed a higher MPE in terms of morphine potentiation (43/44%) showed analgesic effects as single agents, without having anxiolytic or antidepressant properties. The amino-piperidinyl derivative 6 p displayed a similar dose-response relationship to morphine, but was 3 times more potent. ECV Editio Cantor Verlag, Aulendorf (Germany).

Quinazolines and 1,4-benzodiazepines. XXVI. 1,2-Dihydroquinazoline 3-oxides.

-